A bacterium isolated from the intestines of Japanese tree frogs has completely eliminated colorectal tumors in mice with a single intravenous injection, achieving results that outperformed both chemotherapy and immune checkpoint inhibitors in direct comparisons. The finding, published in the journal Gut Microbes by scientists at Japan's Advanced Institute of Science and Technology (JAIST), is one of the most striking pre-clinical results reported in cancer biology in recent memory.
Scientists at JAIST identified a naturally occurring bacterium from the intestines of Japanese tree frogs that demonstrated remarkable anticancer activity in mice, according to a ScienceDaily report published July 10, 2026 that brought renewed national attention to the research. The bacterium, Ewingella americana, was isolated from Dryophytes japonicus — the Japanese tree frog — and was found to be the most potent of 45 bacterial strains screened from the intestines of three amphibian and reptile species.
In a mouse model of colorectal cancer, a single intravenous dose of E. americana completely eliminated tumors, producing a 100% complete response rate. When the surviving mice were later re-exposed to cancer cells, none developed new tumors — suggesting the treatment had generated durable immune memory rather than simply killing visible tumor tissue.
These results are from animal experiments. E. americana has not been tested in human patients, and no clinical trials have been announced. The distance between a 100 percent response in mice and a proven human treatment is substantial.
Why This Matters
Colorectal cancer is the second leading cause of cancer-related death in the United States, accounting for approximately 50,000 American deaths per year. Despite advances in surgical technique, chemotherapy, and immunotherapy, patients with metastatic colorectal cancer — cancer that has spread beyond the colon — continue to face poor outcomes. Five-year survival rates for stage IV colorectal cancer remain under 15 percent.
The interest in bacterial cancer therapy is not new. Researchers have known for over a century that some bacterial infections can trigger tumor regression in humans — an observation first documented in the 1800s by physician William Coley, who used bacterial preparations to treat cancer patients. More recently, the FDA-approved bladder cancer treatment BCG (Bacillus Calmette-Guérin) remains a standard immunotherapy for non-muscle-invasive bladder cancer.
What makes the E. americana research distinctive is the mechanism: unlike most previous bacterial cancer research, which focused on altering the gut microbiome indirectly through diet, probiotics, or fecal microbiota transplants, this work takes a direct approach — isolating, culturing, and delivering individual bacterial strains intravenously to attack tumors. The bacteria are not genetically engineered. They are naturally occurring.
What We Know So Far
The research team, led by Professor Eijiro Miyako at JAIST, began with an ecological hypothesis: many amphibians and reptiles rarely develop spontaneous tumors despite living in environments rich in pathogens and physiological stressors. The researchers hypothesized that gut microbes in those animals might contain strains with inherent anticancer properties.
They collected 45 bacterial strains from the intestines of Japanese tree frogs, Japanese fire-belly newts, and Japanese grass lizards. After screening for anticancer activity, nine strains showed promise. E. americana was the most potent.
The mechanism involves two complementary effects. First, as a facultative anaerobic bacterium — one that can survive both with and without oxygen — E. americana preferentially accumulates in the hypoxic (low-oxygen) environment of tumors, where it thrives and rapidly multiplies. Bacterial counts within tumors increase approximately 3,000-fold within 24 hours of administration. This selective accumulation means the bacterium targets the tumor rather than healthy tissue.
Second, E. americana activates the immune system. Within hours of administration, tumors become infiltrated with T cells, B cells, and neutrophils, accompanied by surges in key inflammatory cytokines including TNF-alpha and IFN-gamma. This dual mechanism — direct tumor cytotoxicity plus immune activation — may explain why the treatment generated durable immune memory, protecting re-challenged mice from tumor regrowth.
In the same experimental framework, the bacterium significantly outperformed both liposomal doxorubicin (a standard chemotherapy agent also known as the "red devil") and anti-PD-L1 antibody (an immune checkpoint inhibitor). The comparison was not designed as an FDA-equivalence trial, and comparisons across animal studies carry significant caveats.
Safety data in the mouse experiments were reassuring: E. americana was cleared from the bloodstream within 24 hours of injection, did not colonize healthy organs such as the liver, lungs, or kidneys, and treated mice experienced only mild, temporary inflammation over a 60-day observation period with zero systemic toxicity.
Where the Research Stands
The Gut Microbes study was published in December 2025 and generated significant international attention at that time. ScienceDaily's July 10, 2026 feature brought renewed mainstream attention to the findings as the field of oncolytic bacteria research has continued to develop.
The JAIST research team plans to test Ewingella americana against breast, pancreatic, and skin cancers, extending the work beyond colorectal cancer, and additional safety and mechanistic studies are expected. No human clinical trial has been announced. The path from animal study to human clinical trial typically involves years of additional pre-clinical work, including testing in larger animals, dose-finding studies, manufacturing scale-up, and regulatory review.
What Doctors and Experts Say
Professor Eijiro Miyako of JAIST, the lead researcher, said in the study that E. americana functions through a dual-action mechanism: direct tumor cell killing and robust activation of host immunity, leading to enhanced T cell, neutrophil, and B cell-mediated tumor attack. He described the approach as representing an innovative therapeutic strategy distinct from current microbiome-focused cancer research.
The broader scientific community has noted that naturally occurring microbes from non-human species represent a largely unexplored reservoir of potentially therapeutic agents — a point that the E. americana findings illustrate vividly. The ecological logic underlying the research — that animals rarely developing cancer despite exposure to tumor-promoting stressors may harbor protective microbes — has generated interest across oncology, microbiology, and ecology.
What the Evidence Shows and What It Does Not
This is where the evidence box is essential.
MedicalDaily Evidence Check
- Study type: Pre-clinical animal study using immunocompetent mouse model of colorectal cancer
- Published in: Gut Microbes (original publication December 2025); renewed coverage ScienceDaily, July 10, 2026
- Lead researcher: Professor Eijiro Miyako, Japan Advanced Institute of Science and Technology (JAIST)
- DOI: 10.1080/19490976.2025.2599562
- What it found: Single intravenous dose of E. americana achieved 100% complete tumor elimination in mice; durable immune memory confirmed; outperformed chemotherapy (liposomal doxorubicin) and immune checkpoint inhibitor (anti-PD-L1) in head-to-head comparisons; no systemic toxicity over 60 days
- What it did not prove: Efficacy or safety in human patients; results in mouse models frequently do not translate to human outcomes; no clinical trial has been announced
- What readers should know: This is compelling early-stage research that deserves continued investigation. It is not a cure, not a treatment, and not available to patients. Do not make treatment decisions based on pre-clinical animal research.
Who This Research Is Most Relevant To
This research does not yet have direct clinical relevance to any patient. It is relevant to:
- Cancer researchers studying oncolytic bacteria and tumor-directed microbial therapies
- Oncologists tracking the emerging field of bacterial cancer therapy
- Patients with colorectal cancer and their families who are following developments in early-stage research — with the understanding that this research is years from any potential human application
- Science journalists and science policy professionals tracking the growing intersection of microbiology and oncology
Symptoms and Warning Signs to Watch For
Colorectal cancer often develops without symptoms in its earliest, most treatable stages. The American Cancer Society and CDC recommend colorectal cancer screening beginning at age 45 for average-risk adults — a recommendation many people are not following. Symptoms that may indicate colorectal cancer and warrant prompt medical evaluation include:
- Blood in the stool or rectal bleeding
- A persistent change in bowel habits lasting more than a few weeks
- Persistent abdominal cramps, gas, or pain
- A feeling that the bowel does not empty completely
- Unexplained weakness or fatigue
- Unintentional weight loss
Do not wait for symptoms before seeking screening. Colonoscopy, stool DNA testing, and FIT (fecal immunochemical test) are all covered screening options for eligible adults.
What You Can Do Now
- If you are 45 or older and have not completed colorectal cancer screening, contact your primary care doctor to schedule one. Screening finds cancer early, when it is most treatable.
- If you or a family member has a history of colorectal cancer or colorectal polyps, ask about earlier and more frequent screening schedules.
- Track developments in oncolytic bacteria research through peer-reviewed sources — the journal Gut Microbes and the National Cancer Institute's news releases are reliable starting points.
- If you are currently in treatment for colorectal cancer, speak with your oncologist before adjusting any treatment based on news coverage of pre-clinical research. Do not delay or alter standard-of-care treatment based on animal studies.
Cost and Access: What Patients Should Know
E. americana is not available as a treatment, is not in clinical trials, and has no cost or access implications for patients at this time.
For patients currently managing colorectal cancer, financial assistance programs are available through the Colorectal Cancer Alliance, the Patient Advocate Foundation, and the Cancer Care national helpline. Colorectal cancer treatment is covered by Medicare and most insurance plans for eligible diagnoses.
What Happens Next
The JAIST team has indicated plans to test E. americana in additional cancer models including breast, pancreatic, and skin cancers. Mechanistic studies to further characterize how the bacterium selectively accumulates in tumors and activates immune responses are also expected. A next step toward potential human application would be testing in non-human primates — a significant additional stage of pre-clinical research before any human trial consideration.
MedicalDaily will report on any new pre-clinical results, announcement of human trials, or regulatory developments related to E. americana or the broader field of bacterial cancer therapy.
The Bottom Line
A bacterium from the Japanese tree frog has achieved results in colorectal cancer that would be extraordinary if they hold up in human beings — complete tumor elimination, durable immune memory, and a safety profile that outperformed established cancer therapies. The research is real, the results are striking, and scientists are paying serious attention to it. But it is a mouse study. The history of oncology is full of compounds that were miraculous in mice and failed in humans. Readers should follow this research with interest, and not with the assumption that it represents an imminent breakthrough for cancer patients.
